<p><p>Sun Pharmaceutical Industries said on Thursday the <a href="http://businesstoday.intoday.in/story/usfda-bans-imports-from-sun-pharmaceutical-gujarat-plant/1/204244.html" mce_href="http://businesstoday.intoday.in/story/usfda-bans-imports-from-sun-pharmaceutical-gujarat-plant/1/204244.html" target="_blank">US Food and Drug Administration's (USFDA)</a> decision to ban import of products from its Karkhadi plant in Gujarat will not hurt the company much financially.</p><p>The facility is a "dedicated" cephalosporin plant and the USFDA move will have little financial impact on the company, a Sun Pharma spokeswoman told <i>Business Today</i>. She did not elaborate.</p><p>Analysts say the company can source cephalosporin, a broad-spectrum antibiotic that is considered a low-value active pharmaceutical ingredient (API), from other facilities or from vendors, and so can escape any financial hit. </p><p>Earlier Thursday, the company said in a statement the USFDA move followed <a href="http://businesstoday.intoday.in/story/sun-pharmaceutical-seeks-to-enter-japan-generics-market/1/204030.html" mce_href="http://businesstoday.intoday.in/story/sun-pharmaceutical-seeks-to-enter-japan-generics-market/1/204030.html" target="_blank">an inspection of the facility</a> that identified some non-compliance of good manufacturing practices regulations. The drugmaker added that it has initiated several corrective steps to address the observations made by the US regulator.</p><p>Analysts also say that the development could be a "perception hit" for the company given that it is the first such ban on an Indian facility. An analyst says that even if the development leads to only a two to three per cent impact on sales, it would hurt the company's image. </p><p>Shares of Sun Pharmaceutical recovered a tad in afternoon trade after falling more than six per cent in the morning. The shares were down about four per cent at Rs 580.40 on the Bombay Stock Exchange.</p><p> </p></p>
<p>Sun Pharmaceutical Industries said on Thursday the <a href="http://businesstoday.intoday.in/story/usfda-bans-imports-from-sun-pharmaceutical-gujarat-plant/1/204244.html" mce_href="http://businesstoday.intoday.in/story/usfda-bans-imports-from-sun-pharmaceutical-gujarat-plant/1/204244.html" target="_blank">US Food and Drug Administration's (USFDA)</a> decision to ban import of products from its Karkhadi plant in Gujarat will not hurt the company much financially.</p>
<p>The facility is a "dedicated" cephalosporin plant and the USFDA move will have little financial impact on the company, a Sun Pharma spokeswoman told <i>Business Today</i>. She did not elaborate.</p>
<p>Analysts say the company can source cephalosporin, a broad-spectrum antibiotic that is considered a low-value active pharmaceutical ingredient (API), from other facilities or from vendors, and so can escape any financial hit. </p>
<p>Earlier Thursday, the company said in a statement the USFDA move followed <a href="http://businesstoday.intoday.in/story/sun-pharmaceutical-seeks-to-enter-japan-generics-market/1/204030.html" mce_href="http://businesstoday.intoday.in/story/sun-pharmaceutical-seeks-to-enter-japan-generics-market/1/204030.html" target="_blank">an inspection of the facility</a> that identified some non-compliance of good manufacturing practices regulations. The drugmaker added that it has initiated several corrective steps to address the observations made by the US regulator.</p>
<p>Analysts also say that the development could be a "perception hit" for the company given that it is the first such ban on an Indian facility. An analyst says that even if the development leads to only a two to three per cent impact on sales, it would hurt the company's image. </p>
<p>Shares of Sun Pharmaceutical recovered a tad in afternoon trade after falling more than six per cent in the morning. The shares were down about four per cent at Rs 580.40 on the Bombay Stock Exchange.</p>
<p> </p>
